昆药集团
(600422)
| 流通市值：61.62亿 | | | 总市值：61.62亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,643,045,313.73 | 836,158,258.4 | 6,575,214,133.55 | 4,751,206,077.58 |
| 营业总成本 | 1,961,200,668.75 | 1,005,316,275.73 | 6,335,560,770.88 | 4,530,354,855.67 |
| 其他经营收益 | | | | |
| 营业利润 | -390,851,897.35 | -134,001,212.92 | 448,507,950.06 | 379,298,300.11 |
| 利润总额 | -395,676,831.18 | -138,290,887.81 | 473,557,838.67 | 378,421,050.69 |
| 净利润 | -369,694,713.72 | -144,847,651.79 | 419,052,861.68 | 323,404,751.99 |
| 每股收益 | | | | |
| 其他综合收益 | -1,485,007.07 | -1,449,310.54 | -12,037,693.62 | 29,191.86 |
| 综合收益总额 | -371,179,720.79 | -146,296,962.33 | 407,015,168.06 | 323,433,943.85 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 6,920,155,558.04 | 7,123,806,677.48 | 7,723,739,881.55 | 7,961,178,600.97 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,060,157,621.22 | 4,091,596,597.77 | 4,049,824,526.9 | 4,044,953,367.66 |
| 资产总计 | 10,980,313,179.26 | 11,215,403,275.25 | 11,773,564,408.45 | 12,006,131,968.63 |
| 流动负债: | | | | |
| 流动负债合计 | 3,552,745,860.52 | 3,411,923,430.74 | 3,825,689,164.7 | 4,123,871,040.5 |
| 非流动负债: | | | | |
| 非流动负债合计 | 990,153,273.11 | 1,005,932,579.48 | 1,006,470,657.09 | 1,026,542,116.53 |
| 负债合计 | 4,542,899,133.63 | 4,417,856,010.22 | 4,832,159,821.79 | 5,150,413,157.03 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,864,074,777.36 | 5,221,546,495.85 | 5,362,259,636.54 | 5,308,840,393.43 |
| 股东权益合计 | 6,437,414,045.63 | 6,797,547,265.03 | 6,941,404,586.66 | 6,855,718,811.6 |
| 负债和股东权益合计 | 10,980,313,179.26 | 11,215,403,275.25 | 11,773,564,408.45 | 12,006,131,968.63 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,238,582,247.04 | 890,320,952.13 | 7,500,547,034.08 | 5,656,393,363.53 |
| 经营活动现金流出小计 | 2,752,609,623.65 | 1,504,009,741.85 | 7,211,310,931.28 | 5,480,229,696.29 |
| 经营活动产生的现金流量净额 | -514,027,376.61 | -613,688,789.72 | 289,236,102.8 | 176,163,667.24 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,656,167,598.06 | 813,042,541.72 | 5,345,256,380.8 | 2,643,845,819.3 |
| 投资活动现金流出小计 | 1,413,244,714.36 | 843,294,992.01 | 5,982,259,480.97 | 4,118,725,860.54 |
| 投资活动产生的现金流量净额 | 242,922,883.7 | -30,252,450.29 | -637,003,100.17 | -1,474,880,041.24 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 582,692,436.29 | 241,761,560.45 | 1,756,208,570.61 | 1,392,199,133.63 |
| 筹资活动现金流出小计 | 761,209,078.06 | 337,609,378.23 | 2,410,844,094.49 | 1,506,012,944.11 |
| 筹资活动产生的现金流量净额 | -178,516,641.77 | -95,847,817.78 | -654,635,523.88 | -113,813,810.48 |
| 汇率变动对现金及现金等价物的影响 | -2,931,460.87 | -1,835,325.48 | -534,546.4 | 711,822.52 |
| 现金及现金等价物净增加额 | -452,552,595.55 | -741,624,383.27 | -1,002,937,067.65 | -1,411,818,361.96 |
| 期末现金及现金等价物余额 | 678,434,748.57 | 389,362,960.85 | 1,130,987,344.12 | 722,106,049.81 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -452,552,595.55 | - | -1,002,937,067.65 | - |
最新报告期：2026-08-23| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,唐庆雷,张云逸 | -0.06 | 0.40 | 0.55 | 2026-08-23 |